Sociedad Americana de Hirudoterapia

Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study

Research article published in Thrombosis and haemostasis (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosFarmacología salivalBrnthaler T et al. · Thrombosis and haemostasis, 2020

Abstract

BACKGROUND:  For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery. Here we investigated the hypothesis that supplemental fibrinogen might mitigate the inhibitory effects of antiplatelet therapy. METHODS AND RESULTS:  To this end blood from healthy donors was treated in vitro with platelet inhibitors, and in vitro thrombus formation and platelet activation were assessed. Ticagrelor, acetylsalicylic acid, the combination of both, and tirofiban all markedly attenuated the formation of adherent thrombi, when whole blood was perfused through collagen-coated microchannels at physiological shear rates. Addition of fibrinogen restored in vitro thrombus formation in the presence of antiplatelet drugs and heparin. However, platelet activation, as investigated in assays of P-selectin expression and calcium flux, was not altered by fibrinogen supplementation. Most importantly, fibrinogen was able to restore in vitro thrombogenesis in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention. CONCLUSION:  Thus, our in vitro data support the notion that supplementation of fibrinogen influences the perioperative hemostasis in patients undergoing surgery during antiplatelet therapy by promoting thrombogenesis without significantly interfering with platelet activation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAgedAspirinCalcium SignalingFemaleFibrinogenHemorheologyHeparinHirudinsHumansIn Vitro TechniquesMaleMiddle Aged

Resumen

For patients treated with dual antiplatelet therapy, standardized drug-specific 3-to-7 day cessation is recommended prior to major surgery to reach sufficient platelet function recovery.

Por qué esto importa para la hirudoterapia

This in vitro study investigated whether supplemental fibrinogen could restore thrombus formation in whole blood from healthy donors treated with platelet inhibitors (ticagrelor, acetylsalicylic acid, tirofiban, and combinations) plus heparin, using collagen-coated microchannels at physiological shear rates. Fibrinogen restored thrombogenesis without altering platelet activation markers (P-selectin, calcium flux), and showed similar restorative effects in patients on maintenance dual antiplatelet therapy after percutaneous coronary intervention. The abstract does not mention hirudin, leech-derived components, or therapeutic leeching; heparin—not hirudin—is the anticoagulant studied, making this article's relevance to ASH's domain peripheral at best.

Citación

Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study

Brnthaler T et al. · Thrombosis and haemostasis, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.